HDAC9 and adrenal cortex carcinoma: The histone deacetylase (HDAC) inhibitor vorinostat may be particularly relevant for treatment of ACC, as deregulation of chromatin remodeling is observed in about 35% of sequenced tumors (Duvic and Vu, 2007; Marks and Breslow, 2007; Ho et al., 2013).